share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Feb 22 06:52
Summary by Futu AI
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of 6,370 common shares on February 20, 2024, as per the latest SEC filings. The shares were sold at a price of $79.67 each, totaling approximately $507,498 in value. Prior to this sale, Kulkarni exercised options to acquire 13,250 shares on February 18, 2024, under a transaction classified as an exercise or conversion of derivative security. Following these transactions, Kulkarni directly holds 194,257 shares of the company. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an indirect holding entity.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of 6,370 common shares on February 20, 2024, as per the latest SEC filings. The shares were sold at a price of $79.67 each, totaling approximately $507,498 in value. Prior to this sale, Kulkarni exercised options to acquire 13,250 shares on February 18, 2024, under a transaction classified as an exercise or conversion of derivative security. Following these transactions, Kulkarni directly holds 194,257 shares of the company. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an indirect holding entity.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.